File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer

TitlePhase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer
Authors
Even, CWang, HMLi, SHNgan, KCRDechaphunkul, AZhang, LYen, CJChan, PCChakrabandhu, SMa, BBYTanasanvimon, SLee, VHFLou, PJLi, ZSpira, AISukari, AGuigay, JMcCune, SGonzalez-Maffe, JSzpakowski, SYao, YLiang, HMataraza, JSéchaud, RManenti, LLim, DWT
Issue Date2021
Citation
Clinical Cancer Research, 2021, p. clincanres.0822.2021 How to Cite?
DOI: http://dx.doi.org/10.1158/1078-0432.CCR-21-0822
Persistent Identifierhttp://hdl.handle.net/10722/305311
ISI Accession Number ID
WOS:000726499400001

 

DC FieldValueLanguage
dc.contributor.authorEven, C-
dc.contributor.authorWang, HM-
dc.contributor.authorLi, SH-
dc.contributor.authorNgan, KCR-
dc.contributor.authorDechaphunkul, A-
dc.contributor.authorZhang, L-
dc.contributor.authorYen, CJ-
dc.contributor.authorChan, PC-
dc.contributor.authorChakrabandhu, S-
dc.contributor.authorMa, BBY-
dc.contributor.authorTanasanvimon, S-
dc.contributor.authorLee, VHF-
dc.contributor.authorLou, PJ-
dc.contributor.authorLi, Z-
dc.contributor.authorSpira, AI-
dc.contributor.authorSukari, A-
dc.contributor.authorGuigay, J-
dc.contributor.authorMcCune, S-
dc.contributor.authorGonzalez-Maffe, J-
dc.contributor.authorSzpakowski, S-
dc.contributor.authorYao, Y-
dc.contributor.authorLiang, H-
dc.contributor.authorMataraza, J-
dc.contributor.authorSéchaud, R-
dc.contributor.authorManenti, L-
dc.contributor.authorLim, DWT-
dc.date.accessioned2021-10-20T10:07:37Z-
dc.date.available2021-10-20T10:07:37Z-
dc.date.issued2021-
dc.identifier.citationClinical Cancer Research, 2021, p. clincanres.0822.2021-
dc.identifier.urihttp://hdl.handle.net/10722/305311-
dc.languageeng-
dc.relation.ispartofClinical Cancer Research-
dc.titlePhase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer-
dc.typeArticle-
dc.identifier.emailNgan, KCR: rkcngan@hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.authorityNgan, KCR=rp02371-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.doi10.1158/1078-0432.CCR-21-0822-
dc.identifier.scopuseid_2-s2.0-85120495726-
dc.identifier.hkuros327893-
dc.identifier.spageclincanres.0822.2021-
dc.identifier.epageclincanres.0822.2021-
dc.identifier.isiWOS:000726499400001-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats